PURPOSE OF REVIEW: Laparoscopic radical nephrectomy has been developed and applied for patients with renal cell carcinoma since 1992. The number of patients undergoing laparoscopic radical nephrectomy has increased explosively worldwide in recent years, and laparoscopy is now extended to patients with advanced disease. It is very important to clarify the present status of laparoscopic radical nephrectomy among the treatment modalities for patients with renal cell carcinoma. RECENT FINDINGS: Laparoscopic radical nephrectomy has a minimally invasive nature as well as comparable long-term cancer control in patients with pT1-3a renal cell carcinoma to open surgery. It is technically applicable for N1-2 disease and T3b disease if the tumor thrombus is within the renal vein. Also, it is feasible as a cytoreductive surgery for patients with M1 disease. SUMMARY: Laparoscopic radical nephrectomy is a standard treatment modality for T1-3a renal cell carcinoma patients. It is also available for treating patients with N1-2 disease, and for patients with M1 disease as a cytoreductive surgery.
PURPOSE OF REVIEW: Laparoscopic radical nephrectomy has been developed and applied for patients with renal cell carcinoma since 1992. The number of patients undergoing laparoscopic radical nephrectomy has increased explosively worldwide in recent years, and laparoscopy is now extended to patients with advanced disease. It is very important to clarify the present status of laparoscopic radical nephrectomy among the treatment modalities for patients with renal cell carcinoma. RECENT FINDINGS: Laparoscopic radical nephrectomy has a minimally invasive nature as well as comparable long-term cancer control in patients with pT1-3a renal cell carcinoma to open surgery. It is technically applicable for N1-2 disease and T3b disease if the tumor thrombus is within the renal vein. Also, it is feasible as a cytoreductive surgery for patients with M1 disease. SUMMARY: Laparoscopic radical nephrectomy is a standard treatment modality for T1-3a renal cell carcinomapatients. It is also available for treating patients with N1-2 disease, and for patients with M1 disease as a cytoreductive surgery.
Authors: Stênio de Cássio Zequi; Walter Henriques da Costa; Fernando Korkes; Rodolfo Borges Dos Reis; Wilson Francisco Schreiner Busato; Wagner Eduardo Matheus; Deusdedit Cortez Vieira da Silva Neto; Felipe de Almeida E Paula; Gustavo Franco Carvalhal; Lucas Nogueira; Roni de Carvalho Fernandes; Adriano Gonçalves E Silva; André Deeke Sasse; André P Fay; Denis Leonardo Jardim; Diogo Assed Bastos; Diogo Augusto Rodrigues da Rosa; Evanius Wierman; Fabio Kater; Fabio A Schutz; Fernando Cotait Maluf; Fernando Nunes Galvão de Oliveira; Igor Alexandre Protzner Morbeck; José Augusto Rinck; Karine Martins da Trindade; Manuel Caitano Maia; Vinicius Carrera Souza; Fernando Sabino Marques Monteiro; Andrey Soares Journal: Ther Adv Urol Date: 2019-09-09